Marie Glorie, NP
Adult Medicine · Dallas, GANPI 1972112357
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Lilly USA, LLC at 28.4% of the total. 2025 is the largest year on record at $543, more than ten times the $42 reported in 2022.
Across 64 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$326
- Novo Nordisk$266
- Pfizer$103
- AbbVie$60
- Dexcom, Inc.$50
- Astellas Pharma US Inc$47
- plus $294 from 12 others
What the payments were for
- Food & beverage$1,10296%
- Education$454%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $326 |
| Novo Nordisk | 17 | $266 |
| Pfizer | 6 | $103 |
| AbbVie | 3 | $60 |
| Dexcom, Inc. | 3 | $50 |
| Astellas Pharma US Inc | 2 | $47 |
| Bayer | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Exact Sciences | 2 | $33 |
| Abbott | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Dynavax Technologies Corporation | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Merck | 1 | $18 |
| GSK | 1 | $17 |
| AstraZeneca | 1 | $15 |
How this compares
$1,147 in reported general payments places this provider in the 65th percentile of 43 adult medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $25,701 |
| JanuviaSitagliptin Phosphate | 16 | $16,306 |
| JardianceEmpagliflozin | 16 | $15,301 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $11,171 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,481 |
| SynthroidLevothyroxine Sodium | 25 | $2,251 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,524 |
| Atorvastatin Calcium | 171 | $1,129 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $864 |
| Pravastatin Sodium | 67 | $816 |
| Levothyroxine Sodium | 120 | $804 |
| Rosuvastatin Calcium | 72 | $802 |
| Losartan Potassium | 93 | $728 |
| Lisinopril | 178 | $696 |
| Amlodipine Besylate | 170 | $673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet Xr | $18 | $27,47627 claims |
| Novo NordiskOzempic | $266 | $25,70119 claims |
| Boehringer IngelheimJardiance | $24 | $15,30116 claims |
| GSKBreo Ellipta | $17 | $6,48113 claims |
| AbbVieSynthroid | $60 | $2,25125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 43 adult medicine providers in Georgia.
Other adult medicine in Dallas
- Michael CohenPooler$14K
- Jinne RichardsAlbany$11K
- Charles WilliamsAlpharetta$10K
- Kenneth JonesUnion City$9K
- Katherine McClellanRinggold$7K
- Ewaul PersaudSmyrna$6K
- Jenna Barnes CaronDalton$5K
- Alana VilladaBuford$4K
- Syed UllahDecatur$4K
- Wylie NewtonGainesville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.